dc.contributor.author | Tanrikulu, S. | |
dc.contributor.author | Yalin, G. Y. | |
dc.contributor.author | Canbaz, B. | |
dc.contributor.author | Akyuz, F. | |
dc.contributor.author | Yarman, S. | |
dc.contributor.author | Dogansen, S. C. | |
dc.date.accessioned | 2021-03-03T10:09:06Z | |
dc.date.available | 2021-03-03T10:09:06Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | Yarman S., Yalin G. Y. , Dogansen S. C. , Canbaz B., Tanrikulu S., Akyuz F., "Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis", JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.41, sa.5, ss.559-562, 2016 | |
dc.identifier.issn | 0269-4727 | |
dc.identifier.other | av_20fac006-d65a-4245-a436-6f6320437fec | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/27206 | |
dc.identifier.uri | https://doi.org/10.1111/jcpt.12412 | |
dc.description.abstract | What is known and objectiveSomatostatin analogs control GH/IGF-1 excess in acromegaly. Somatostatin receptors also mediate the complex effects of somatostatin on the gastrointestinal tract and may be defensive in inflammatory bowel diseases, such as ulcerative colitis. We present a patient who showed good response to long-acting octreotide (OCT-LAR) treatment in terms of both acromegaly and ulcerative colitis (UC). | |
dc.language.iso | eng | |
dc.subject | Temel Bilimler | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.title | Double benefit of long-acting somatostatin analogs in a patient with coexistence of acromegaly and ulcerative colitis | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 41 | |
dc.identifier.issue | 5 | |
dc.identifier.startpage | 559 | |
dc.identifier.endpage | 562 | |
dc.contributor.firstauthorID | 235169 | |